Addex Therapeutics Ltd - ADR
ADXN
Get informed when a big investor buys or sells
+ FollowMarket Cap$4.1M
Close$
$2.08
63.1% downside
Current Fair Value
63.1% downsideOvervalued by 63.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $4.10 Million |
|---|---|
| Enterprise Value | $3.30 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-6.88 |
| Beta | 1.99 |
| Outstanding Shares | 1,427,000 |
Return
| Return on Equity | -211.58% |
|---|---|
| Return on Assets | -146.12% |
| Return on Invested Capital | -131.97% |
Valuation & Multiples
| P/E Ratio | -0.72 |
|---|---|
| PEG | -4.47 |
| Price to Sales | - |
| Price to Book Ratio | 2.82 |
| Enterprise Value to Revenue | 15.23 |
| Enterprise Value to EBIT | -0.71 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
June 25, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 24, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Addex Therapeutics Ltd
27 employees
CEO: Tim Dyer